Inhibition of pathological retinal neovascularization by semaphorin 3A

Wenzhen Yu,1 Yujing Bai,1 Na Han,2 Fei Wang,1 Min Zhao,1 Lvzhen Huang,1 Xiaoxin Li1

(The first two authors contributed equally to this paper.)

1Key Laboratory of Vision Loss and Restoration, Ministry of Education, Department of Ophthalmology, Peking University People’s Hospital, Beijing, China; 2Department of Orthopaedics and Trauma, Peking University People’s Hospital, Beijing, China

Objective: Pathological retinal angiogenesis is a major cause of vision loss. Semaphorin 3A (Sema3A), a chemorepellent guidance protein, plays crucial roles in neural and vascular patterning. To identify its role in retinal neovascularization, we investigated its antiangiogenic effects.

Methods: Human umbilical vein endothelial cells (HUVECs) were used for the in vitro study, and an oxygen-induced retinopathy (OIR) mouse model was used for the in vivo study. The HUVECs were incubated with Sema3A, and cell proliferation, migration, apoptosis, cell cycle, tube formation, and c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases (p38 MAPK) signaling pathways were measured using Cell Counting Kit-8, Transwell, flow cytometry, Matrigel assays, and western blot. C57BL/6J mouse pups were exposed to 75% oxygen for 5 days and then brought to room air and injected with Sema3A intravitreally. At postnatal day 18, the retinal nonperfused areas were measured. The in vitro and in vivo vascular endothelial growth factor-165 (VEGF165) secretion was measured using enzyme-linked immunosorbent assay.

Results: Sema3A not only inhibited VEGF165-induced proliferation, but also induced cell cycle arrest in a dose-dependent manner. Furthermore, Sema3A inhibited migration and tube formation, both in general and in VEGF165-containing culture medium. Using an enzyme-linked immunosorbent assay, we showed that Sema3A did not affect VEGF165 secretion, but it did impede VEGF165 function. Additionally, Sema3A significantly inhibited the phosphorylation of the JNK and p38 MAPK signaling pathways. When administered intravitreally, Sema3A reduced the pathological vascular changes seen in the retinal neovascularization OIR model.

Conclusions: These results suggest that the administration of Sema3A could be a useful therapeutic strategy for preventing hypoxia/ischemic-induced retinal neovascularization.

Pathological retinal angiogenesis is a major cause of vision loss in various diseases, including retinopathy of prematurity (ROP), diabetic retinopathy, and age-related macular degeneration (AMD) [1,2]. Vascular endothelial growth factor (VEGF) and its receptors have been demonstrated to play major roles in the generation and progression of neovascular eye diseases; they have therefore become the ideal targets for antiangiogenesis therapy [3]. However, anti-VEGF agents can induce local and systemic side effects. It has been shown that the systematic use of anti-VEGF drugs will induce hypertension because of vascular contraction [1], and intravitreous injection will result in the contraction of the retina’s proliferative membranes due to the action of the fibroblast cells and other components in the membranes, which could cause retinal holes [4]. Thus, the exploration and evaluation of new antineovascularization compounds is greatly needed.

Semaphorin 3A (Sema3A) is an endogenous secreted protein that belongs to the class 3 semaphorin family (Sema3), which were originally identified as axonal guidance molecules and were also implicated in vessel pathfinding and network formation [5]. Neurontilin 1 and 2 (Nrnl and Nrp2) and the type A/D plexins (Pxls) act as the ligands binding and the signal transducing subunits of the Sema3 receptor complexes on the surface of endothelial cells (ECs) [5]. As a special member of the Sema3 family, Sema3A binds to Nrnl exclusively at first and then combines with PlexinA1–4 as a complex (Nrnl/PlexA1–4). In this receptor complex, Nrnl acts as a binding element, while PlexA1–4 acts as a signal-transducing element [6]. Since the discovery of Sema3A, a variety of studies have reported its effects on neuronal cell migration, tumor metastasis, and vascular genesis [7–9]. The effects of Sema3A on retina pathological neovascularization, however, have not been documented. In the present study, we extensively investigated the antiangiogenic effects and possible mechanisms of Sema3A in retinal neovascularization.
for the first time. The encouraging results of our study provide a useful therapeutic strategy for the treatment of retinal neovascularization.

METHODS

Cells and animals: Human umbilical vein endothelial cells (HUVECs, American type culture collection (ATCC), CRL-1730) were cultured as previously described [10]. HUVECs were cultured in 10% fetal bovine serum containing culture medium as ATCC recommended. Neonatal mice (C57BL/6J) were obtained from the animal center of Peking University and were raised in the animal room of the Peking University People’s Hospital. This study adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and was performed in accordance with the guidelines provided by the Animal Care Use Committee of Peking University. The animals were housed with free access to laboratory food and water and were kept in a 12h:12h light-dark cycle.

Proliferation assays and vascular endothelial growth factor-165 measurement by enzyme-linked immunosorbent assay in human umbilical vein endothelial cells: Sema3A (Sino Biologic Inc., 50,631-M01H) was incubated with HUVECs in 96-well plates for 24, 48, and 72 h at concentrations of 250 ng/ml and 500 ng/ml in either general culture medium (10% fetal bovine serum [FBS]) or VEGF_{165} (25 ng/ml, R&D, 293-VE-containing medium). Cell Counting Kit-8 (Dojindo, Shanghai) assays were performed according to the manufacturer’s instructions. Briefly, after adding 10 ml of CCK-8 to each well, the cells were incubated at 37 °C for another 30–60 min. Absorbance was measured with an enzyme-linked immunosorbent assay (ELISA) plate reader at a wavelength of 450 nm. Each experiment was repeated in five wells and was duplicated at least three times. With the same treatment process, after incubation times of 24, 48, and 72 h, the cell culture supernatant was harvested and centrifuged. Free VEGF_{165} protein in the culture medium was measured by an ELISA kit (Bostar, EK0575) according to the manufacturer’s instructions.

Migration assay: HUVECs migration was assayed by Transwell (Corning, US, Cat#3422) as described previously [10]. Briefly, 2×10^{4} cells were placed in the top part of a serum-free medium. Dulbecco’s Modified Eagle Medium (DMEM, Hyclone, Grand Island, NY; containing 10% FBS) with 250 ng/ml and 500 ng/ml Sema3A or Sema3A with VEGF_{165} (25 ng/ml) was placed in the bottom chamber. All migration assays were conducted at 37 °C for 5 h, and then the cells were fixed with 4% paraformaldehyde (PFA) and stained with 4’,6-diamidino-2’-phenylindole dihydrochloride (DAPI, Roche, Germany, Cat# 236276). The cells that had not migrated were removed with a cotton swab, and the membrane was imaged with fluorescence microscopy (Zeiss Axiophot, Thornwood, NY). Cells from five random view fields were counted, and the average was used for statistical analysis.

Flow cytometry analysis of human umbilical vein endothelial cell apoptosis and the cell cycle: HUVECs apoptosis study (FITC Annexin V Apoptosis Detection Kit; BD Science) and cell cycle analysis (Cycletest Plus DNA Reagent Kit; BD Science) were performed according to the manufacturer’s instructions and as previously reported [10]. Briefly, the HUVECs (1×10^{6}) were seeded in six-well plates and incubated for 24, 48, and 72 h with Sema3A or VEGF_{165} plus Sema3A, or were used as controls. The samples were analyzed by flow cytometer (FACSCalibur; BD Biosciences, Franklin Lakes, NJ), and the experiments were performed in triplicate and repeated three times.

Tube formation study: According to the manufacturer’s instructions and our previous report [10], 150 μl of Matrigel (BD Sciences, Cat#354234) solution was poured into 48-well plates and was then incubated at 37 °C for 30 min. The HUVECs (5×10^{3} per well) were treated with Sema3A or Sema3A plus VEGF_{165} or were used as controls, and then the cells were seeded on the Matrigel and cultured for 8–10 h. The networks in the Matrigel from five randomly chosen fields were counted and photographed. The length of the tube was measured by Image J software. The experiments were repeated three times.

Western blot analysis: The HUVECs were prepared with protein extraction and protease inhibitor kits (Pierce). After centrifugation, the supernatant was collected, and the protein lysate was measured with a BCA protein assay kit (Pierce) according to the manufacturer’s instructions. Briefly, diluted albumin standards were prepared for calculate the formula. 25 ml unknown samples were loaded into 96-well plate in three repeated wells. After adding 200 ml working agent into the wells, mix plate thoroughly on a plate shaker for 30 s. Cover plate and incubate at 37°C for 30 min, and measure the absorbance of 560 nm on a plate reader. Equal amounts of protein were loaded and analyzed by immunoblotting. The proteins were visualized with enhanced chemiluminescence western blot detection reagents (Pierce). The band densities of c-Jun N-terminal kinase (JNK, CST, Cat#9258), phosphorylation-c-Jun N-terminal kinase (p-JNK, CST, Cat#4668), p38 mitogen-activated protein kinases (p38 MAPK, CST, Cat#8690), and phosphorylation-p38 MAPK (p-p38 MAPK, CST, Cat#4511) were tested. Western blot analysis was
repeated three times, and qualitatively similar results were obtained.

**Induction of an oxygen-induced retinopathy mouse model and assessment of the nonperfusion area:** C57BL/6J pups were exposed to hyperoxia (75% oxygen) for five days, from postnatal day 7 (P7) to P12, and were brought back to normoxia from P12 to P17. At P12, the oxygen-induced retinopathy (OIR) mice were injected with Sema3A (1.5 μl, 100 ng/ml, 250 ng/ml) or immunoglobulin G (IgG) intravitreally (1.5 μl, 250 ng/ml). At P18, the mice were sacrificed and were then perfused with 0.5 ml of PBS containing 50 mg of 2×10^6 MW fluorescein–dextran–fluorescein isothiocyanate (Sigma, St. Louis, MO). After eye fixation, the retinas were flat mounted and photographed. The nonperfused areas (NPA) were analyzed with Image J software. The ratio of the NPA compared to the whole retina was determined.

**Retinal vascular endothelial growth factor-165 concentration measurement:** After injections with Sema3A or control for 5 days, the C57 pups were sacrificed at P18, and the retinas were separated as stated in the western blot analysis section. VEGF<sub>165</sub> (pg/ml protein) in the clarified supernatant was measured with an ELISA kit (Bostar, EK0541). All of the experiments for the ELISA test were performed in five pups, and each experiment was repeated three times.

**Statistical analysis:** The data analysis was performed using the statistical software Prism 5 (GraphPad Software Inc., San Diego, CA). All of the data were presented as the mean±standard error of the mean (SEM). The differences were evaluated with analysis of variance followed by the Student–Newman–Keuls test for multiple comparisons and the Student t test for pairwise comparisons. A value of p<0.05 was considered to be a statistically significant difference.
RESULTS

Semaphorin 3A inhibits vascular endothelial growth factor-165-induced human umbilical vein endothelial cell proliferation: Sema3A did not inhibit HUVEC proliferation in the general culture medium, even at a high concentration (Sema3A 500 ng/ml; compared to the 10% FBS group), but it did inhibit VEGF<sub>165</sub>-induced HUVECs proliferation significantly at both concentrations and at variable time points when compared to the VEGF<sub>165</sub>-treated group (p<0.05; Figure 1A-C).

Effects of semaphorin 3A on vascular endothelial growth factor-165 secretion: There was no increase in free VEGF<sub>165</sub> secretion in the Sema3A-treated HUVEC groups (Figure 1D-F, the columns of 3A 250 ng/ml and 3A 500 ng/ml groups) under the general culture condition; on the other hand, under the VEGF<sub>165</sub> (25 ng/ml) stimulation condition, the detected free VEGF<sub>165</sub> was much higher in the Sema3A-treated HUVEC (Figure 1D-F, the columns of VEGF+3A 250 ng/ml and VEGF+3A 500 ng/ml groups; p<0.05). The above results indicate that Sema3A did not affect the VEGF<sub>165</sub> secretion in HUVECs under the general culture condition, but rather inhibited the utilization ability of exogenous VEGF<sub>165</sub> and impeded its functions. These results can explain the proliferation assay results showing that Sema3A only inhibits VEGF<sub>165</sub>-induced HUVEC proliferation.

Semaphorin 3A inhibits human umbilical vein endothelial cell migration: The migration study was assessed with a Transwell assay. As shown in Figure 2, the number of cells that passed through the membrane in the Sema3A-treated HUVEC groups was significantly lower than was the number in the control groups at both concentrations (Figure 2A,C,F, p<0.05). In the VEGF<sub>165</sub>-stimulated group, Sema3A was also able to inhibit the crossing of the HUVECs (Figure 2A,D,E, p<0.05).

Semaphorin 3A inhibits human umbilical vein endothelial cell tube formation: The Matrigel assay is one of the most widely used methods to evaluate the angiogenesis ability of ECs in vitro. In our study, Sema3A-treated HUVECs showed an impaired capacity to form a regular network at concentrations of 250 ng/ml and 500 ng/ml (Figure 3), both in the general culture medium and in the VEGF<sub>165</sub>-containing medium. The
length of the angiogenesis network also showed a statistically significant difference as compared to the control groups.

**Semaphorin 3A induces cell cycle arrest in human umbilical vein endothelial cells but does not induce apoptosis:** Fluorescence-activated cell sorting was used to evaluate the cell cycle and early and late apoptosis effects. In our study, there was no significant difference between the Sema3A treated groups and the control groups (data not shown) in the apoptosis study. However, Sema3A was able to induce HUVEC cell cycle arrest both in the general culture medium and in the VEGF	extsubscript{165}-induced conditions (Figure 4).

**Western blot analysis of the JNK and p38MAPK signaling pathways:** The immunoblot analysis of the JNK, p-JNK, p38MAPK, and p-p38MAPK signaling pathways revealed that Sema3A inhibited the phosphorylation of JNK both in the general culture medium and in the VEGF	extsubscript{165}-containing culture medium (Figure 5A,B); Sema3A also inhibited the phosphorylation of p38MAPK in the VEGF-containing culture medium (Figure 5C,D).

**Semaphorin 3A protects against oxygen-induced retinopathy retinal pathological angiogenesis while not affecting retina vascular endothelial growth factor-165 secretion:** Sema3A has been shown to inhibit tumor growth [11]. To determine whether Sema3A had an antiangiogenesis effect in the OIR mouse model, Sema3A (100 ng/ml, 250 ng/ml) and IgG (250 ng/ml) were injected intravitreally into the right eyes of retinopathic mice at P12 and to age-matched normal pups. As shown in Figure 6, Sema3A intravitreous injection significantly reduced the neovascularized areas (Figure 6A-F) and reduced abnormal vessel growth (Figure 6G,H). In the ELISA assay that measured VEGF	extsubscript{165} in the retina of each treated
group, however, there was no significant difference between the untreated OIR and the Sema3A-treated retina (Figure 7).

DISCUSSION

Recently, the application of anti-VEGF therapies, i.e., ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech), has played an important role in the treatment of neovascular eye diseases such as ROP, AMD, and central retinal vein occlusion [12]. With the extensive application of these treatments, however, local and systemic side effects appear [13, 14], and the limitation of anti-VEGF in retinal neovascularization diseases has aroused the attention of ophthalmologists. Previous studies have stated that intravitreal anti-VEGF treatment causes increased fibrosis in proliferative diabetic retinopathy patients and AMD patients, which is due to the imbalance of VEGF with regard to other growth factors such as connective tissue growth factor [4,15,16]. The unexpected fibrosis tissue will result in membrane contraction, causing retina hole formation and other complications. Therefore, there is a great need to explore and evaluate new antineovascularization compounds or to find supplemental treatment strategies beyond anti-VEGF. As an endogenous antiangiogenesis agent, Sema3A has been studied in tumor biology [17]. In the Sema3 family, Sema3A has been shown to have antiangiogenic properties, and numerous studies have suggested that Sema3A inhibits ECs proliferation, migration, and survival, although the exact mechanism remains unclear [11,16]. In our study, we showed that Sema3A inhibits VEGF-induced HUVEC proliferation, but not in a general culture medium. This inhibition occurs because Sema3A inhibits the utilization of VEGF based on our angiogenesis. In the present study, we showed that (a) Sema3A does not affect the secretion of VEGF either in vitro or in vivo (Figure 1 and Figure 7); (b) Sema3A can inhibit VEGF-induced cell biological effects, such as proliferation, migration, and neovascularization, and its role could involve competing with VEGF and a possible independent VEGF receptor (VEGFR) effect on HUVECs (Figure 1, Figure 2, Figure 3, and Figure 4); (c) Sema3A can inhibit neovascularization in hypoxia/ischemia-induced retinopathy (Figure 6); (d) the antiangiogenesis effects of Sema 3A could be the results of inhibiting the phosphorylation of the JNK and p38 MAPK signaling pathways (Figure 5).

Semaphorins, also known as collapsins, were initially described as axon guidance factors that affect the development of the nervous system [5]. As blood vessels and nerves are structurally similar complex branched systems, the Semas have also been implicated in vessel formation [5]. Class 3 semaphorins (Sema3) represent one of the vertebrate families of semaphorins; they are known to play an important role in tumor biology [17]. In the Sema3 family, Sema3A has been shown to have antiangiogenic properties, and numerous studies have suggested that Sema3A inhibits ECs proliferation, migration, and survival, although the exact mechanism remains unclear [11,16]. In our study, we showed that Sema3A inhibits VEGF-induced HUVEC proliferation, but not in a general culture medium. This inhibition occurs because Sema3A inhibits the utilization of VEGF based on our angiogenesis. 

To our knowledge, this is the first experimental study to address the role of Sema3A in pathological retinal
ELISA results in both HUVECs and retinas, and the mechanisms of this inhibition likely result from Sema3A competing with VEGF165 for their binding site on neuropilin receptors [19].

Sema3A and VEGF165 share a common coreceptor, specifically Nrp-1 [20]. VEGF family members mediate their downstream effects by binding to neuropilins and forming complexes with VEGFRs, which are analogous to
the Sema3-neuropilin-Plxn complex [17]. While Nrp-1 is not required for VEGF function, it can enhance the signaling of VEGF through one of its receptor tyrosine kinases, VEGFR2 [16]. This is evidenced by our western blot analysis showing that the VEGFR2 downstream signalings of JNK and p38MAPK phosphorylation were downregulated. In addition to the antiproliferation effect, Sema3A inhibits HUVEC migration and tube formation, both with and without VEGF165. These results are consistent with previous studies that showed that Sema3A impairs EC adhesion and migration by negatively regulating the integrin-mediated adhesion of cultured ECs and experimental angiogenesis in vitro and in vivo, as well as inducing the disappearance of EC focal contacts, which is followed by the collapse of the actin cytoskeleton [7,21-23]. Thus, we supposed that besides a simple binding competition between Sema3A and VEGF165, there should be other, independent VEGFR effects on HUVEC functions.

Although a previous study showed that Sema3A promoted the apoptosis of ECs [24], we did not replicate these results in our study, and we only found that Sema3A induced cell cycle arrest. This result might have been observed because we used immortalized cell lines, while the other studies used primary ECs [24]. Sema3A's induction of cell cycle arrest in a general culture condition (Figure 4) contradicts the results wherein Sema3A did not affect HUVEC proliferation (Figure 1). The reasons for this may have to do with the sensitivity of our detection method (Cell Counting Kit-8) or that Sema3A did not influence intracellular dehydrogenase. Further mechanisms need to be tested and discussed in future studies.

In the in vivo study, we used a broadly accepted hypoxia/ischemic retinopathy animal model, an OIR mouse model with a mechanism similar to that of ROP [25,26]. In this study, we also showed that Sema3A intravitreal injection in normal mice did not induce changes in the VEGF165 expression (Figure 7). Even in the OIR model, Sema3A did not affect the secretion of VEGF165, but it was able to reduce the non-perfusion area and the pathological angiogenesis (Figure 6). Another explanation for this result is that Sema3A can compete with VEGF165 for binding to its receptor, ultimately impeding the function of VEGF165.

In summary, we comprehensively studied the antiangiogenesis effects of Sema3A both in vitro and in vivo, and found that Sema3A could effectively inhibit the growth of retinal neovascularization in an OIR model. Our data suggested that Sema3A may be an innovative approach for future therapeutic strategies against other types of angiogenesis as well. Sema3A could be an adjunctive therapeutic strategy for VEGF165 inhibitors. To our knowledge, this study provides the first evidence of the anti–retinal neovascularization potential of Sema3A.

ACKNOWLEDGMENTS
We thank Xin Yu, PhD for the help with the FACS analysis. This work was supported by the National Basic Research Program of China (973 Program, 2011CB510200) for LXX and Peking University People’s Hospital Research and Development Fund for BYJ (RDB2012–24).

REFERENCES
1. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438:960-6. [PMID: 16355161].
2. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28:1-18. [PMID: 19026761].
3. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29. [PMID: 12597922].
4. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, Klaassen I, Schlingemann RO. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmo 2012; 96:587-90. [PMID: 22289291].

Figure 7. Effects of semaphorin 3A on retina vascular endothelial growth factor-165 (VEGF165) secretion. This figure shows the VEGF165 in the oxygen-induced retinopathy (OIR) animal model (n=4) and the semaphorin 3A (Sema3A)-treated OIR model (n=4). The y-axis represents the VEGF165 secretion ratios of the different treatment groups comparing to the 10% fetal bovine serum (FBS) treatment group. Each experiment was repeated three separate times. All of the data are presented as the mean± standard error of the mean (SEM).
5. Eichmann A, Le Noble F, Autiero M, Carmeliet P. Guidance of vascular and neural network formation. Curr Opin Neurobiol 2005; 15:108-15. [PMID: 15721752].

6. Roth L, Koncina E, Satkauskas S, Cremel G, Aunis D, Bagnard D. The many faces of semaphorins: from development to pathology. Cell Mol Life Sci 2009; 66:649-66. [PMID: 18953684].

7. Kruger RP, Auranldt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol 2005; 6:789-800. [PMID: 16314868].

8. Hinck L. The versatile roles of “axon guidance” cues in tissue morphogenesis. Dev Cell 2004; 7:783-93. [PMID: 15572123].

9. Melani M, Weinstein BM. Common factors regulating patterning of the nervous and vascular systems. Annu Rev Cell Dev Biol 2010; 26:639-65. [PMID: 19575651].

10. Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, Li XX. Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 2012; 342:131-9. [PMID: 22495066].

11. Capparuccia L, Tamagnone L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment–two sides of a coin. J Cell Sci 2009; 122:1723-36. [PMID: 19461072].

12. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, Pinheiro MM, Zanetti CR. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009; 28:117-44. [PMID: 19114125].

13. van der Reis MI, De Jong-Hesse Y, Ringens PJ, Hendriks F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011; 31:1449-69. [PMID: 21817960].

14. Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, Bagby SP, Kolunam G, Kowalski J, Oyer JA, Bunting S, Lindner JR. Cardiovascular and Systemic Microvascular Effects of Anti-Vascular Endothelial Growth Factor Therapy for Cancer. J Am Coll Cardiol 2012; 60:618-25. [PMID: 22703929].

15. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology 2011; 118:101-10. [PMID: 20678805].

16. Hwang JC, Del Priore LV, Freund KB, Chang S, Iranmanesh R. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2011; 42:6-11. [PMID: 20954648].

17. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008; 8:632-45. [PMID: 18580951].

18. Gaur P, Bielenberg DR, Samuel S, Bose D, Zhou Y, Gray MJ, Dallas NA, Fan F, Xia L, Lu J, Ellis LM. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res 2009; 15:6763-70. [PMID: 19887479].

19. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagesbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999; 146:233-42. [PMID: 10402473].

20. Derijck AA, Van Erp S, Pasterkamp RJ. Semaphorin signaling: molecular switches at the midline. Trends Cell Biol 2010; 20:568-76. [PMID: 20655749].

21. Klagesbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 2005; 16:535-48. [PMID: 15979925].

22. Tamagnone L, Comoglio PM. To move or not to move? Semaphorin signalling in cell migration. EMBO Rep 2004; 5:536-61. [PMID: 15060572].

23. Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural connectivity. Curr Opin Neurobiol 2003; 13:79-89. [PMID: 12593985].

24. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007; 282:26294-305. [PMID: 17569671].

25. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 2010; 29:500-19. [PMID: 20488255].

26. Lutty GA, McLeod DS. Retinal vascular development and oxygen-induced retinopathy: a role for adenosine. Prog Retin Eye Res 2003; 22:95-111. [PMID: 12597925].